医学
低温消融
前列腺癌
组织病理学
放射科
接收机工作特性
前列腺
冷冻外科
冷冻疗法
活检
癌症
病理
内科学
烧蚀
作者
Inga Peters,Katja Derlin,Matti Peperhove,Bennet Hensen,Stefanie Pertschy,Mathias Wolters,Christoph A. J. von Klot,Frank Wacker,Susanne Hellms
出处
期刊:Future Oncology
[Future Medicine]
日期:2022-03-08
卷期号:18 (14): 1705-1716
被引量:1
标识
DOI:10.2217/fon-2021-1146
摘要
Aim: To share our experience after 28 cryoablation treatments for prostate cancer (PCa) with histopathology, clinical data and MRI as the follow-up methods. Methods: Clinical follow-up comprised prostate-specific antigen (PSA)-measurements, PSA-density and quality of life-parameters. multi-parametric (mp)MRI pre- and post-cryoablation were retrospectively re-analyzed in 23 cases using Likert scores. Follow-up-histopathology was performed via MRI/ultrasound fusion-guided and/or systematic biopsy. Receiver operating characteristic curve analysis was performed. Results: 17 PCa (61%) were diagnosed within 12-month post-cryotherapy (infield and out-of-field disease). PSA levels and PSA density were not significantly different between patients with or without PCa recurrence. mpMRI can characterize the decrease in prostate volume and necrosis. Area under the curve for the detection of PCa was 81% (global Likert scores), 74-87% (T2), 78% (diffusion weighted imaging) and 57-78% (dynamic contrast enhanced imaging; Youden-selected cutoff ≥3). Conclusion: Besides histopathological evaluation and control biopsy, MRI might have the potential to accurately detect PCa after cryotherapy. Clinical data and interdisciplinary communication are required for efficient monitoring after cryoablation treatments for PCa.
科研通智能强力驱动
Strongly Powered by AbleSci AI